A 2026 randomized trial found that a daily synbiotic supplement lowered inflammation markers in critically ill children with sepsis, with IL-6 falling 92.57% within the supplement group. According to research reviewed by Gram, however, it did not shorten hospital stays or change survival rates in the 54 children studied.
Sepsis is a dangerous reaction to infection that can cause severe inflammation throughout the body, and it is a leading cause of death and long-term harm in children. According to research reviewed by Gram, a 2026 randomized trial tested whether a daily synbiotic powder, which combines helpful bacteria with the food they feed on, could calm this inflammation. Fifty-four critically ill children in a pediatric intensive care unit were randomly assigned to take either the supplement or a placebo for 4 to 7 days. The children who took the supplement had lower levels of three key inflammation markers. However, the supplement did not shorten hospital stays, reduce time on breathing machines, or change survival rates. The findings are promising but early, and larger studies are needed before any clinical recommendations can be made.
Key Statistics
A 2026 randomized controlled trial of 54 critically ill children with sepsis found that a daily synbiotic supplement significantly lowered CRP, IL-6, and TNF-alpha compared with placebo.
In the 2026 trial of 54 children with sepsis, IL-6 levels fell by 92.57% in the synbiotic group, but length of hospital stay and mortality did not differ significantly from the placebo group.
The 2026 synbiotic trial in children with sepsis tested a 4 to 7 day course of two sachets daily and found statistically significant reductions in CRP (p = 0.004) compared with placebo.
The Quick Take
- What they studied: Researchers asked whether giving critically ill children a daily synbiotic supplement, a mix of beneficial bacteria and the fiber-like foods they feed on, could reduce harmful inflammation and improve recovery from sepsis.
- Who participated: Fifty-four children with sepsis who were being treated in a pediatric intensive care unit. Each child was randomly placed into either the supplement group or the placebo group, and neither the children’s families nor the medical staff knew which group each child was in.
- Key finding: After treatment, children who took the supplement had significantly lower levels of CRP, IL-6, and TNF-alpha, three blood markers of inflammation (all p values below 0.05). IL-6 dropped by 92.57% within the supplement group, but the supplement did not change hospital stay length, ventilator use, antibiotic duration, or death rates.
- What it means for you: The results suggest that this type of supplement may help calm inflammation in critically ill children. It should not be treated as a proven way to speed recovery or save lives. Parents of seriously ill children should talk with the medical team before any supplement is added to treatment.
The Research Details
This was a randomized controlled trial, which is one of the strongest ways to test whether a treatment causes a change. Children were assigned by chance to receive either the synbiotic product, called KidiLact, or a placebo, which looked and was taken the same way but contained no active ingredients.
Each child took two sachets a day for 4 to 7 days while receiving standard intensive care. Researchers measured blood levels of inflammation markers, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), before and after the treatment period.
The study was also triple blind, meaning that the children, their caregivers, and the researchers analyzing the results were all kept unaware of which group each child belonged to. This reduces the chance that expectations could influence the outcome.
Randomization spreads out differences between children, such as age or illness severity, so that the two groups are more alike. Blinding keeps people’s hopes or worries from shaping how symptoms are reported or how results are read. Together, these features make it more likely that any差 in inflammation levels came from the supplement itself.
The trial was registered in advance with the Iranian Registry of Clinical Trials, which reduces the risk of changing the goals after seeing the results. Its design is rigorous. However, the small group size means the study may have missed real differences in clinical outcomes, and the authors themselves note that larger studies are needed. Results from 54 children should be viewed as an early signal rather than a final answer.
What the Results Show
The main result was that children who took the synbiotic supplement had lower inflammation markers after the treatment period than children who took the placebo. CRP was significantly lower (p = 0.004), and both IL-6 (p below 0.001) and TNF-alpha (p below 0.001) were significantly lower as well. CRP is a protein the liver releases during inflammation, while IL-6 and TNF-alpha are signaling molecules that help drive the body’s immune response. In sepsis, these markers often rise to dangerous levels.
Within the supplement group, IL-6 levels fell by 92.57% and TNF-alpha levels fell by 39.63%. These are changes measured within the same group over time, so they do not directly show how much larger the drop was compared with the placebo group. The statistical comparisons between groups, however, were significant for both markers.
The lower inflammation levels suggest that the supplement may influence the immune response in a meaningful way. Because sepsis involves a severe and sometimes harmful immune reaction, reducing these signals could be relevant. Still, a change in a blood marker is not the same as a change in how a child feels or recovers.
The researchers also found no meaningful differences in the outcomes that matter most to families, such as how long children stayed in the hospital or intensive care, how long they needed breathing support, how long they needed antibiotics, or whether they survived.
The study looked at several secondary outcomes, including length of hospital stay, time in the pediatric intensive care unit, days on mechanical ventilation, duration of antibiotic therapy, and mortality. None of these differed significantly between the supplement and placebo groups. This matters because lower inflammation alone does not guarantee faster recovery or better survival. Clinical outcomes depend on many factors, including the infection itself, the child’s overall health, and the quality of care. With only 54 participants, the study may not have had enough people to detect small but real effects on these outcomes.
Research on probiotics and synbiotics in sepsis has grown in recent years, based on the idea that the gut microbiome, the community of bacteria living in the digestive system, plays a role in how the body responds to severe infection. Earlier studies in adults and children have reported mixed results, with some showing reduced inflammation and others finding little benefit. This trial adds evidence that inflammation markers may respond to synbiotics in critically ill children, while also reinforcing that these changes have not yet translated into clear clinical benefits.
The most important limitation is the small sample of 54 children. Small trials can produce results that look strong but do not hold up in larger groups, and they may miss real effects on hospital stays or survival. The study was also limited to children in one intensive care setting, so results may not apply to other hospitals, age groups, or types of infection.
The treatment period was short, lasting 4 to 7 days, so the study cannot show whether longer use would lead to different results. It also measured inflammation at specific points in time, which does not reveal how levels changed over the full course of illness.
Finally, the researchers did not identify exactly how the supplement affected the children’s gut bacteria, so the mechanism behind the inflammation changes remains unclear.
The Bottom Line
Moderate confidence: the trial suggests that a synbiotic supplement may lower certain inflammation markers in critically ill children with sepsis. Low confidence: that it improves recovery, shortens hospital stays, or reduces deaths, since the study found no differences in these outcomes. Any use in clinical care should wait for larger trials that confirm these early findings and examine patient-centered outcomes.
Pediatric intensive care clinicians, researchers studying sepsis or the gut microbiome, and parents of children in intensive care may find this research relevant. Healthy adults and children not being treated for sepsis should not apply these findings to themselves, because the study focused only on critically ill children. Anyone considering a supplement for a seriously ill child should speak with the treating medical team first.
In this study, inflammation markers changed within the 4 to 7 day treatment period. Whether any changes in these markers would ever lead to shorter hospital stays or better long-term health remains unknown. Families and clinicians should not expect clinical improvements based on this trial alone, and any benefits from future research would likely take years to confirm.
Frequently Asked Questions
Can a probiotic or synbiotic supplement help children with sepsis recover faster?
A 2026 randomized trial of 54 critically ill children found that a synbiotic supplement lowered inflammation markers but did not shorten hospital stays, ventilator use, or antibiotic duration. Faster recovery has not been demonstrated, and larger studies are needed.
What did the 2026 synbiotic sepsis study in children find about inflammation?
Children who took a synbiotic supplement for 4 to 7 days had significantly lower CRP, IL-6, and TNF-alpha levels than children on placebo. Within the supplement group, IL-6 dropped by 92.57% and TNF-alpha dropped by 39.63%.
What is sepsis and why is inflammation a concern?
Sepsis is a life-threatening reaction to infection in which the body’s immune response damages its own organs. Inflammation markers such as IL-6 and CRP rise during this reaction, so researchers study ways to calm them down.
Should parents give probiotics to a child in intensive care?
Parents should not start any probiotic or synbiotic for a child in intensive care without the medical team’s approval. Current evidence from a small trial is promising for inflammation but does not show improved clinical outcomes or survival.
Want to Apply This Research?
- If a user is using a supplement under medical guidance, log the number of sachets taken each day and any symptoms such as fever, appetite, or digestive changes. Recording these details alongside lab results shared by the care team can help track patterns over the treatment period.
- Encourage users to review any new supplement with a doctor or pharmacist before starting it, especially for children or people with serious illness. The app can prompt users to bring a written list of current supplements and medications to every appointment.
- Over the long term, users can track general gut health habits such as fiber intake, fermented food servings, and digestive comfort. Sharing these trends with a healthcare provider can add useful context to any future lab results, though the app should not replace medical monitoring for serious conditions like sepsis.
This article summarizes a single, small clinical trial in critically ill children with sepsis and is for general information only. It is not medical advice. Sepsis is a medical emergency. Never start, stop, or change any supplement or treatment for a child without consulting a qualified healthcare professional.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.